The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify
Wednesday, August 26 – (MedPage Today) — In January, Jeff La Marca got a prescription for the popular weight loss drug tirzepatide (Zepbound). But he couldn’t afford the $750 monthly price tag.
Then Medicare launched an 18-month pilot program that offers GLP-1 medications…
People’s bodies are changing in the age of Ozempic. How are we meant to talk about it?
Wednesday, August 26 – Discussing people’s bodies can be fraught. We asked eating disorder experts how to do so – or not – responsiblyIn the age of Ozempic and people being open about plastic surgery, discussion about people’s bodies is rife. At the same time, nobody seems quite sure how to talk about them, as shown by recent coverage of celebrities like Ariana Grande.It is a fraught topic. We asked eating disorder experts for guidelines to follow when talking about other people’s bodies, and how to do so without doing harm. Continue reading…
The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify
Wednesday, August 26 – The new Medicare GLP-1 Bridge program promises eligible beneficiaries access to popular weight loss drugs for as little as $50 a month. But for some, having the very medical conditions these drugs are approved to treat means they don’t qualify for the discount.
Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug
Tuesday, August 25 – Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass.
Smart probiotics can sense high blood sugar and release GLP-1 on demand
Monday, August 24 – For people living with diabetes, managing blood sugar can mean constantly watching the clock, keeping meals and medications on schedule and staying alert to changes in glucose levels. While little can be done about timed meals, researchers have developed a biological system that detects rising blood sugar levels and automatically responds by releasing medication to bring glucose back down.
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy
Saturday, August 22 – The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.
Ozempic does something unexpected to the brain’s hunger neurons
Saturday, August 22 – Ozempic may work in the brain in almost the opposite way scientists expected, activating hunger-linked neurons that appear essential for sustaining fat loss. The surprising discovery in mice could reveal new targets for developing even more effective obesity drugs.
Sugary Drinks and Stomach Cancer; GLP-1 Use in IBD; Fiber Supplements for IBS
Friday, August 21 – (MedPage Today) — GLP-1 Use in IBD
Doc Imposter Sold GLP-1s; Fraudster Fugitive Nabbed; Plastic Surgeon’s Lawsuits
Friday, August 21 – (MedPage Today) — A Chicago man was charged with a scheme to impersonate doctors to obtain unauthorized GLP-1 medications on behalf of individuals who paid him, the Department of Justice (DOJ) said.
A pair of shareholder groups are suing UnitedHealth…
Medicare’s pilot GLP-1 discount program has a catch. Some sick patients don’t qualify
Thursday, August 20 – Medicare launched a pilot program that could streamline the process to get GLP-1s, with some seniors paying just $50 a month. But many people with the most serious illnesses won’t get that discount.